P95 and Julius Clinical Merge to Create a Premier Global CRO
P95 and Julius Clinical are joining forces to establish a leading global, full-service clinical research organization (CRO). This newly formed entity will leverage their combined expertise across multiple sectors including neuroscience, cardio-renal-metabolic areas, infectious diseases, and vaccines. With a workforce of more than 500 professionals spread across over 25 countries, they aim to deliver effective clinical development and real-world evidence (RWE) programs worldwide.
Combining Strengths for Enhanced Service
The merger unites the strengths of Julius Clinical’s global clinical trial proficiency and P95’s expertise in epidemiology, resulting in a well-rounded, science-led platform. This partnership is designed to support biopharmaceuticals and public health initiatives throughout the entire development lifecycle.
In recent years, both organizations successfully initiated numerous programs in areas such as neuroscience, cardio-renal-metabolic, and infectious diseases. This experience includes extensive global clinical trials, epidemiological studies, and RWE projects, enhancing their reputation in the field.
Leadership Structure Post-Merger
The leadership of the merged company is headed by Bassem Saleh, M.D., who has been appointed CEO of the combined organizations. Dr. Thomas Verstraeten, the founder, and former CEO of P95, will remain involved as a Senior Advisor and Board Member, ensuring continuity and strategic oversight during this integration phase.
Dr. Saleh expressed excitement about this merger, stating, "P95 and Julius Clinical share a solid scientific foundation and a mutual mission to improve health outcomes globally. My commitment extends to our partners and teams that have propelled our successes, as we strive to deliver exceptional, science-led research that makes a difference in global health. "
Future Prospects and Expansion Plans
Dr. Verstraeten shared similar sentiments, reflecting on the past achievements of P95 over a decade, particularly its role in advancing scientific integrity and public health partnerships worldwide. The combination of both companies is expected to yield a new phase of growth, broadening reach and scalability, ultimately benefiting clients and partners engaged in vital research.
The newly formed organization will continue to receive support from Ampersand Capital Partners, a notable investor in both businesses. The partnership with Ampersand is pivotal for expanding their global reach and reinforcing their operational capabilities to meet demanding growth strategies.
Global Presence and Expertise
With staff distributed across North America, Europe, Africa, Latin America, and Asia-Pacific, this organization boasts a global presence complemented by local expertise. Their comprehensive team encompasses clinical operations, epidemiology, biostatistics, data science, medical advice, and scientific consulting, and they are prepared to deliver a spectrum of service models tailored to client needs. The merger provides an array of benefits for clients—ranging from large pharmaceutical enterprises to innovative biotech firms, as well as prestigious public health institutions.
About P95 and Julius Clinical
P95 stands as a significant figure in epidemiology and clinical solutions, with a concentration on vaccines and infectious diseases. Based in Belgium, the company operates regional hubs across South Africa, Colombia, the USA, and Thailand, showcasing robust CRO capabilities with a skilled team of approximately 300 in over 30 countries. Their offerings are vast, including Phase I-IV clinical trials, epidemiological and RWE services, and consultancy for vaccine development.
Founded in 2008, Julius Clinical has established itself as a premier CRO based in the Netherlands, specializing in areas including the central nervous system, cardio-metabolic, renal, and rare diseases. With an extensive portfolio of over 400 clinical trials and a patient recruitment exceeding 300,000 globally, their focus remains on delivering tailored services that reflect operational excellence.
Frequently Asked Questions
What is the significance of the merger between P95 and Julius Clinical?
The merger aims to leverage complementary strengths in clinical research to enhance service delivery across various medical fields.
Who will lead the newly formed organization?
Bassem Saleh, M.D., will serve as the CEO, with Thomas Verstraeten advising the organization as a Board Member.
What areas of expertise will the merged organization focus on?
The organization will focus on neuroscience, cardio-renal-metabolic, infectious diseases, and vaccines.
How will this merger benefit clients and partners?
Clients will benefit from a broader range of services, enhanced scientific depth, and an integrated approach to clinical trials and RWE strategies.
What support will the company receive for growth strategies?
Ampersand Capital Partners will continue supporting the new organization to aid in global expansion and capability building.
